By Mariam Sunny (Reuters) -Biohaven said on Monday its experimental treatment for a rare neuromuscular disorder failed to significantly improve motor function in a late-stage trial, sending the shares ...

CVS Caremark has removed several therapies to treat patients with diabetes in favor of newer products and generics, and is ...

We’ve debated immigration since Native Americans encountered a group of migrants from England who decided to settle in ...

Highlights:,Biogen Inc. (BIIB) has underperformed the broader market and key healthcare ETFs in recent years.,The company’s ...

Cambridge, Massachusetts-based Biogen Inc. ( BIIB) discovers, develops, manufactures, and delivers therapies for treating ...

Jefferies analyst Michael Yee maintained a Buy rating on Biogen (BIIB – Research Report) today and set a price target of $250.00. The company’s shares opened today at $159.99. Don't Miss our Black ...

Biogen (NASDAQ:BIIB – Free Report) had its price objective decreased by Mizuho from $251.00 to $207.00 in a research note published on Thursday,Benzinga reports. Mizuho currently has an outperform ...

Sage Therapeutics discontinued development of its lead candidate dalzanemdor after a third clinical failure, leading analysts ...